Remo CRO

News

GlycoMimetics Enrolls First Patient in Global Phase 3 Clinical Trial of Uproleselan in Relapsed/Refractory Acute Myeloid Leukemia

11.27 2018.

ROCKVILLE, Md.–(BUSINESS WIRE)–Nov. 19, 2018– GlycoMimetics, Inc. (NASDAQ: GLYC) announced today dosing of the first patient in the company’s Phase 3 clinical trial of uproleselan (GMI-1271) in relapsed/refractory AML. The trial’s… Details

Minerva Neurosciences Announces Results of Dose Escalation Study Evaluating Roluperidone (MIN-101) Administered at Supra-Therapeutic Doses in Healthy Volunteers

11.27 2018.

WALTHAM, Mass., Nov. 19, 2018 (GLOBE NEWSWIRE) — Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced the… Details

Theravance Biopharma Announces First Patient Dosed in Phase 2 Study of TD-1473 in Patients with Crohn's Disease

11.27 2018.

DUBLIN, Nov. 20, 2018 /PRNewswire/ — Theravance Biopharma, Inc. (NASDAQ: TBPH) (“Theravance Biopharma” or the “Company”) today announced dosing of the first patient in a Phase 2 clinical trial of TD-1473 in patients with… Details

Landmark PALISADE Trial of AR101 Published in New England Journal of Medicine

11.27 2018.

BRISBANE, Calif.–(BUSINESS WIRE)–Nov. 18, 2018– Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that the New England Journal of Medicine… Details

How aspirin and omega-3 may reduce cancer risk

11.21 2018.

A new clinical trial suggests that taking aspirin and an omega-3 fatty acid can decrease the number of precancerous growths in the colon. Details

'Breakthrough' treatment for peanut allergy awaits FDA check

11.20 2018.

Millions of people live with peanut allergy, for which there is currently no available treatment. Thanks to a new study, though, this may soon change. Details